Kinase Inhibitor

P-Glycoprotein Inhibitors

Cytochrome P450 2C8 Inhibitors

Breast Cancer Resistance Protein Inhibitors

Cytochrome P450 3A Inhibitors

Multidrug and Toxin Extrusion Transporter 1 Inhibitors

Rearranged during Transfection (RET) Inhibitors

Carcinoma, Non-Small-Cell Lung

Thyroid Neoplasms

<section class="Section" data-sectioncode="34089-3"><a name="s62"></a><a name="section-9"></a><p></p><h1>11 DESCRIPTION</h1><p class="First">RETEVMO contains selpercatinib, a kinase inhibitor. The molecular formula for selpercatinib is C<span class="Sub">29</span>H<span class="Sub">31</span>N<span class="Sub">7</span>O<span class="Sub">3</span> and the molecular weight is 525.61 g/mol. The chemical name is 6-(2-hydroxy-2-methylpropoxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile. Selpercatinib has the following chemical structure:</p><div class="Figure"><a name="f01"></a><img alt="Chemical Structure
" src="retevmo-uspi-chem.jpg"/></div><p>Selpercatinib is a white to light yellow powder that is slightly hygroscopic. The aqueous solubility of selpercatinib is pH dependent, from sparingly soluble at low pH to practically insoluble at neutral pH.</p><p>RETEVMO capsules contain either 40 mg or 80 mg of selpercatinib in hard gelatin capsules for oral use. Each capsule contains inactive ingredients of colloidal silicon dioxide and microcrystalline cellulose. The 40 mg capsule shell is composed of gelatin, titanium dioxide, ferric oxide black and black ink. The 80 mg capsule shell is composed of gelatin, titanium dioxide, FD&amp;C blue #1 and black ink. The black ink is composed of shellac, potassium hydroxide and ferric oxide black.</p><p>RETEVMO tablets contain 40 mg, 80 mg, 120 mg or 160 mg of selpercatinib as film coated, debossed tablets for oral use. Each tablet contains inactive ingredients of croscarmellose sodium, hydroxypropyl cellulose, mannitol, microcrystalline cellulose, and sodium stearyl fumarate. The tablet film coating material contains polyvinyl alcohol, titanium dioxide, polyethylene glycol, and talc. Additionally, the film coating of the 40 mg, 80 mg, and 120 mg tablets contains ferrosoferric oxide and the film coating of the 80 mg, 120 mg, and 160 mg tablets contain ferric oxide.</p></section>

RETEVMO

selpercatinib

selpercatinib 40 MG Oral Capsule

Retevmo

selpercatinib 40 MG Oral Capsule [Retevmo]

selpercatinib 80 MG Oral Capsule

selpercatinib 80 MG Oral Capsule [Retevmo]

selpercatinib 120 MG Oral Tablet

selpercatinib 120 MG Oral Tablet [Retevmo]

selpercatinib 160 MG Oral Tablet

selpercatinib 160 MG Oral Tablet [Retevmo]

selpercatinib 40 MG Oral Tablet

selpercatinib 40 MG Oral Tablet [Retevmo]

selpercatinib 80 MG Oral Tablet

selpercatinib 80 MG Oral Tablet [Retevmo]

Psoriasis (PsO)

Psoriatic Arthritis (PsA)

Ankylosing Spondylitis (AS)

Nonradiographic Axial Spondyloarthritis

Taltz

Juvenile Idiopathic Arthritis

Hidradenitis Suppurativa (HS)

Cosentyx

Siliq

Tremfya

Crohn's Disease (CD)

Ulcerative Colitis (UC)

Stelara

Skyrizi

Ilumya

Migraine

Cluster Headache

Migraine Prevention

Emgality

Qulipta

Acute Migraine

Ubrelvy

Nurtec ODT

Vyepti

Aimovig

Ajovy

Breast Cancer: HR+ (HER2-)

Verzenio

Ibrance

Kisqali

Atopic Dermatitis (Eczema)

Cibinqo

Eucrisa

Asthma (injectable)

Asthma OCS Dependent

Nasal Polyposis

Eosinophilic Esophagitis (EoE)

Prurigo Nodularis

Dupixent

Opzelura

Adbry

NSCLC ALK+ OR ROS1+ Disease

Lorbrena

Alecensa

Alunbrig

NSCLC cMET Mutation

Xalkori

Rheumatoid Arthritis (RA)

Xeljanz

Uveitis

Graft Versus Host Disease (GVHD)

Orencia

COVID-19 Treatment

Alopecia Areata

Olumiant

Multiple Sclerosis (MS)

Secondary Progressive Multiple Sclerosis

Zeposia

Rinvoq

Entyvio

Report Adverse Event

Prescribing Information 

Medication Guide 

Submit MSL Request 

Pharmacy List 

Retevmo Access, Distribution, and Reimbursement Guide 

Coverage Authorization Request 

Coverage Authorization Appeals 

Letter of Medical Necessity 

My Right Dose - Dose Exchange Program 

Enroll in Bridge Program 

Enroll in Patient Savings Program 

Reimbursement Information 

Other HCP Resources 

Comprehensive Support Program 

Patient Stories 

Patient Resources 

About Retevmo 

Side Effects 

Instructions For Use - Thyroid Cancer 

Instructions For Use - Lung Cancer 

Lilly Cares Foundation

Taking Retevmo